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Store-operated Ca2+ entry (SOCE) is a dynamic pro-
cess that leads to refilling of endoplasmic reticulum
(ER) Ca2+ stores through reversible gating of plasma
membrane Ca2+ channels by the ER Ca2+ sensor Stromal
Interaction Molecule 1 (STIM1). Pathogenic reductions
in b-cell ER Ca2+ have been observed in diabetes. How-
ever, a role for impaired SOCE in this phenotype has not
been tested. We measured the expression of SOCE
molecular components in human and rodent models of
diabetes and found a specific reduction in STIM1 mRNA
and protein levels in human islets fromdonorswith type 2
diabetes (T2D), islets from hyperglycemic streptozotocin-
treated mice, and INS-1 cells (rat insulinoma cells)
treated with proinflammatory cytokines and palmitate.
Pharmacologic SOCE inhibitors led to impaired islet
Ca2+ oscillations and insulin secretion, and these effects
were phenocopied by b-cell STIM1 deletion. STIM1 de-
letion also led to reduced ER Ca2+ storage and increased
ER stress, whereas STIM1 gain of function rescued
b-cell survival under proinflammatory conditions and
improved insulin secretion in human islets from do-
nors with T2D. Taken together, these data suggest
that the loss of STIM1 and impaired SOCE contribute to
ER Ca2+ dyshomeostasis under diabetic conditions,
whereas efforts to restore SOCE-mediated Ca2+ tran-
sients may have the potential to improve b-cell health
and function.
Reductions in b-cell endoplasmic reticulum (ER) calcium
(Ca2+) levels contribute to the pathophysiology of both
type 1 diabetes and type 2 diabetes (T2D) and lead to
decreased insulin secretion, activation of intracellular
stress pathways, and b-cell death. Steady-state ER Ca2+
levels are maintained by the balance of Ca2+ transport into
the ER lumen by the sarco-ER Ca2+ ATPase (SERCA) pumps
and Ca2+ release via the inositol triphosphate receptors
and ryanodine receptors (RyRs) (1–4). ER Ca2+ depletion
also triggers a tightly regulated rescue mechanism that
serves to replenish ER Ca2+ stores through a family of
channels referred to as store-operated or Ca2+ release–
activated channels (5–7). This process, known as store-
operated Ca2+ entry (SOCE), is initiated by the dissociation
of Ca2+ from the ER Ca2+ sensor, Stromal Interaction
Molecule 1 (STIM1), followed by STIM1 oligomerization
and translocation to the ER/plasmalemmal junctional re-
gions (8). Here, STIM1 complexes with selective Orai Ca2+
channels (9) and nonspecific transient receptor potential
canonical channel 1 (TRPC1), leading to the activation of
Ca2+ influx from the extracellular space, with subsequent
transfer of Ca2+ into the ER lumen (10,11). Although path-
ologic reductions in SERCA-mediated ER Ca2+ uptake and
dysregulated RyR-mediated ER Ca2+ leakage have been
described in the diabetic b-cell (4,12,13), a role for im-
paired b-cell SOCE in this phenotype remains untested.
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In other cell types, SOCE Ca2+ transients have been
implicated in a number of signaling pathways, including
those that regulate proliferation, growth, inflammation,
apoptosis, and lipogenesis. In addition, defective SOCE has
been associated with several clinical syndromes, including
immunodeficiency, myopathy, Alzheimer disease, and vas-
cular disease (14–18). Recently, pharmacologic inhibitors
of SOCE or dominant-negative forms of either Orai1 or
TRPC1 were shown to decrease insulin secretion in rat
islets and clonal b-cell lines (11), while STIM1 was also
shown to interact with the sulfonylurea receptor 1 subunit
of the KATP channel and regulate b-cell KATP activity (19).
Given these recent implications of SOCE in the regu-
lation of insulin secretion, we hypothesized that dysfunc-
tional b-cell SOCE may likewise contribute to diabetes
pathogenesis. To this end, we profiled SOCE and the
expression of SOCE molecular components in multiple
diabetic models, including islets from streptozotocin
(STZ)-treated mice, human and mouse islets and rat
insulinoma (INS-1) cells treated with proinflammatory
cytokines, INS-1 cells treated with palmitate, and human
islets isolated from donors with T2D. Our data revealed
a preferential loss of STIM1 expression but preserved
expression of Orai1 across these models. Moreover,
b-cell STIM1 loss as well as STIM1 knockdown led to
impaired glucose-stimulated Ca2+ oscillations and insulin
secretion, and increased b-cell susceptibility to ER stress,
whereas STIM1 gain of function rescued these defects. Taken
together, these data define a novel role for altered SOCE in
diabetes and suggest that efforts to restore STIM1 expression
and/or SOCE-mediated Ca2+ transients have the potential
to improve b-cell function and health.
RESEARCH DESIGN AND METHODS
Reagents
Mouse and human interleukin-1b (IL-1b), interferon-g
(IFN-g), and tumor necrosis factor-a (TNF-a) were obtained
from Invitrogen (Carlsbad, CA); and 2-aminoethoxydiphenyl
borate (2-APB), 1-(5-chloronaphthalene-1-sulphonyl)-1H-
hexahydro-1,4-diazepine (ML-9), and tunicamycin (TM)
were obtained from Tocris Bioscience (Bristol, U.K.).
Adenoviruses expressing STIM1 and Cre recombinase
were from ViraQuest Inc. (North Liberty, IA) (19). Small
interfering RNAs (siRNAs) were obtained from GE
Healthcare (Lafayette, CO); and all other chemicals were
from Sigma-Aldrich (St. Louis, MO). Supplementary Tables
1 and 2 contain a complete list of PCR primers and
antibodies.
Animals and Human Islets
Male C57BL/6J mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). At 8 weeks of age, C57BL/6J
were injected intraperitoneally with 50 mg/kg STZ or
normal saline daily for 5 days. Mice with loxP sites flanking
exon 2 of the Stim1 gene were obtained from The Jackson
Laboratory and backcrossed onto a C57BL/6J background
for at least 10 generations. Mice were maintained under
protocols approved by the Indiana University Institutional
Animal Care and Use Committee. Cages were kept in a
standard light/dark cycle with ad libitum access to food
and water.
Cadaveric human islets from donors without diabetes
and donors with T2D were obtained from the Integrated
Islet Distribution Program. The data presented include the
analysis of islets from 8 donors without diabetes (5 female;
3 male) and 11 donors with T2D (7 female; 4 male). The
average age (6SEM) of the donors without diabetes was
45.9 6 10.3 years; the mean BMI was 25.6 6 4.7 kg/m2.
The average age of donors with T2D was 50.9 6 8.9 years;
the average BMI was 33.2 6 7.1 kg/m2.
Cell Culture and Islet Treatments
Rat INS-1 832/13 cells and human and mouse pancreatic
islets were cultured as previously described (20,21).
CRISPR/Cas9 genomic editing was used to create a
STIM1 knockout (KO) INS-1 832/13 cell line in the
Genome Engineering and iPSC Center at Washington
University (St. Louis, MO). To mimic proinflammatory
and diabetic conditions, INS-1 cells were treated with
5 ng/mL IL-1b, and mouse and human islets were treated
with 5 ng/mL IL-1b, 100 ng/mL IFN-g, and 10 ng/mL
TNF-a for 24 h as previously published (12). To induce ER
stress, INS-1 cells were treated with 10 mmol/L TM for 3–
24 h. For viral transduction studies, 50–100 islets were
handpicked within 1 h of isolation or receipt, incubated
with adenovirus for 16 h, followed by an additional 48–
72 h of incubation in freshmediumwithout adenovirus. To
obtain STIM1 KO islets, isolated islets from STIMflox/flox
mice were transduced with an adenovirus encoding Cre
recombinase under control of the cytomegalovirus pro-
moter. Glucose-stimulated insulin secretion (GSIS), immu-
noblot, and immunofluorescence in cultured wild-type
(WT) INS-1 cells, STIM1 KO cells, and isolated mouse
and human islets were performed as previously described
(4,12). Islet GSIS was also measured using the Biorep
Perifusion System (Biorep, Miami Lakes, FL) (22). Twenty-
four hours after isolation, 50 handpicked islets were loaded
into each perifusion chamber; islets were perifused with
Krebs buffer containing 2.8 mmol/L glucose for 20 min,
followed by 16.7 mmol/L glucose for 40 min at a rate of
120 mL/min. Secreted insulin was measured using an ELISA
(Mercodia, Uppsala, Sweden); results were normalized to
DNA content. Quantitative real-time (qRT)-PCR was per-
formed using previously published primer sequences (23)
or primers outlined in Supplementary Table 1. To generate
transmission electron micrographic images, INS-1 cells
were fixed in 2% glutaraldehyde and 4% paraformaldehyde
in 0.1 mol/L sodium cacodylate buffer and transferred to
the Advanced Electron Microscopy Facility at the Univer-
sity of Chicago (Chicago, IL).
Live Cell Imaging
Cytosolic Ca2+ dynamics in INS-1 cells were measured
using the FLIPR Calcium 6 Assay Kit and a FlexStation
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3 Plate Reader (Molecular Devices, Sunnyvale, CA). To
measure SOCE, INS-1 832/13 b-cells were loaded with
Calcium 6 in growth medium containing 11 mmol/L glu-
cose for 2 h. Immediately prior to Ca2+ imaging, cells were
incubated in Ca2+-free Hanks’ balanced salt solution
(HBSS) with the following composition: 138 mmol/L
NaCl, 5.3 mmol/L KCl, 0.34 mmol/L Na2HPO4, 0.44
mmol/L KH2PO4, 4.17 mmol/L NaHCO3, and 5.5 mmol/L
glucose for 4 min. Ca2+ imaging experiments were per-
formed according to the strategy shown in Fig. 1A. Baseline
fluorescence (F0) was measured for a minimum of 10 s
under Ca2+-free conditions and in the presence of
0.5 mmol/L EGTA (Ca2+ chelator), 10 mmol/L verapamil
(L-type voltage-dependent Ca2+ channel blocker), and
200 mmol/L diazoxide (KATP channel opener applied to
prevent voltage-dependent Ca2+ channel activation). Next,
thapsigargin (TG; a SERCA inhibitor) was used to empty
ER Ca2+ stores, followed by supplementation with 2
mmol/L Ca2+ in the media. SOCE was detected as an
elevation of Calcium 6 intensity (vertical red arrow; DF)
Figure 1—Pharmacologic inhibition of SOCE led to impaired insulin secretion and glucose-inducedCa2+ oscillations.A: INS-1 832/13 b-cells
were loaded with Calcium 6, and Ca2+ imaging experiments were performed to measure SOCE, according to the strategy shown. B and C:
Ca2+ imaging was performed with or without known SOCE inhibitors, 50 mmol/L ML-9 and 200 mmol/L 2-APB, in the presence of 5.5 mmol/L
glucose, 200 mmol/L diazoxide, and 10 mmol/L verapamil (Dz + V). ER Ca2+ depletion was induced with 3 mmol/L TG, and SOCE was
quantified as the cytosolic Ca2+ increase after supplementation with 2 mmol/L Ca2+. Results were displayed as the DF/F0 after Ca2+
supplementation. D: GSIS was measured in INS-1 cells pretreated with or without ML-9 and 2-APB and normalized to total protein content.
E–H: Glucose-stimulated Ca2+ imaging was performed using Fura-2 AM in islets isolated from C57BL/6J mice and pretreated with ML-9 or
2-APB. E: Representative cytosolic Ca2+ recording after stimulationwith 15mmol/L glucose. Quantification of the average phase 1 amplitude
(F ), phase 2 (oscillation) amplitude (G), and oscillation period (H). I: Mean insulin concentration profiles during islet perifusion at basal
2.8 mmol/L glucose concentrations (0–20min) and in response to 16.7 mmol/L glucose stimulation (20–60min). DMSO or 200 mmol/L 2-APB
was added to the 16.7 mmol/L glucose buffer. Fifty islets were loaded per chamber, and data are reported as ng/mL insulin normalized to
islet DNA content (n = 3). J: Relative area under curve (AUC) values for first phase (20–30min) and second phase (30–60min) insulin secretion
with DMSO and 2-APB treatment. The numbers of replicates for each experiment are indicated by the open circles. Results are displayed
as the means 6 SEM; *P , 0.05 compared with control (Cont) conditions.
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in response to Ca2+ addition, which was normalized to the
basal F0 (red dotted line), according to the formula DF/F0.
Cytosolic Ca2+ imaging was performed in isolated islets in-
cubated in HBSS buffer supplemented with 2 mmol/L Ca2+
and the ratiometric Ca2+ indicator fura-2-acetoxymethylester
(Fura-2 AM) (Life Technologies) using a Zeiss Z1 microscope
as previously described (4,24).
To directly image ER Ca2+ levels, cells were transfected
with an adenovirus encoding the ER-targeted D4ER probe
expressed under the control of the rat insulin promoter
(23). Fluorescence lifetime imaging microscopy (FLIM) was
used to monitor steady-state ER Ca2+ levels in accordance
with previously published protocols (4,25). For Förster
resonance energy transfer (FRET) experiments, confocal
images were acquired with a Leica TCS SP8 confocal/mul-
tiphoton imaging system (Leica Microsystems, Inc., Buf-
falo Grove, IL). Imaging was performed using a 448-nm
single excitation laser line, and fluorescent emission col-
lected with two hybrid detectors set to 460–500 and 515–
550 nm emission slit widths. Time series images (z stacks)
of two to three stage-registered fields were acquired over
a period of 20 min. Images were analyzed using Leica LAS X
software (version 3.3) to calculate the change in FRET ratio
over time.
Statistical Analysis
Differences between groups were examined for signifi-
cance using either a two-tailed Student t test or one-way
ANOVA followed by the Tukey-Kramer post-test using
GraphPad Prism statistics software (GraphPad Software,
Inc., San Diego, CA). Pearson correlations were used to
analyze the relationships between STIM1 mRNA levels
and donor BMI. Unless indicated, results were displayed
as the mean6 SEM; a P value of,0.05 was used to indicate
a significant difference between groups.
RESULTS
Pharmacologic Inhibition of SOCE Impaired Glucose-
Stimulated Ca2+ Oscillations and Insulin Secretion
To image b-cell SOCE, INS-1 cells were loaded with Cal-
cium 6; Ca2+ imaging experiments were performed accord-
ing to the schematic shown in Fig. 1A and described in
the RESEARCH DESIGN AND METHODS. As shown previously
(26,27), pharmacologic SOCE inhibitors ML-9 and
2-APB reduced the DF/F0 activated in response to ER
Ca2+ depletion (Fig. 1B and C). Moreover, ML-9 and 2-APB
reduced GSIS by 61% and 68%, respectively, in INS-1
b-cells (Fig. 1D). To test whether SOCE inhibitors similarly
impacted glucose-stimulated Ca2+ oscillations, islets from
WT C57BL/6J mice were treated with either ML-9 or
2-APB and then loaded with Fura-2 AM for the analysis
of glucose-stimulated Ca2+ responses (Fig. 1E). Although
pharmacologic inhibition of SOCE had no effect on the
phase 1 DF response to glucose (Fig. 1F), ML-9 and 2-APB
reduced the average amplitude of the oscillatory response
(DF phase 2) and increased the oscillatory period (Fig. 1G
and H). In islet perifusion experiments, the addition of
2-APB to the high-glucose buffer significantly reduced both
first- and second-phase insulin secretion (Fig. 1I and J).
Consistent with the effects observed on glucose-stimulated
Ca2+ oscillations, a more striking effects was observed on
second-phase insulin secretion.
b-Cell STIM1 Expression Was Reduced in Mouse and
Human Models of Diabetes
Next, islets were isolated from STZ or saline-treated
C57BL/6J mice and glucose-stimulated Ca2+ imaging per-
formed. Islets from STZ-treated mice had reduced ampli-
tude of the DF phase 1 and 2 responses and a decreased
oscillatory period (Fig. 2A–E). To test whether observed
changes in calcium signaling may be related to changes in
the expression of the molecular components of the b-cell
SOCE complex, first, we compared the expression levels of
STIM and Orai isoforms in human and mouse islets and
INS-1 cells (Supplementary Fig. 1A–C). In human islets,
mouse islets, and INS-1 cells, STIM1 was expressed at
higher levels compared with STIM2. Orai2 was the most
highly expressed Orai isoform in human islets. In mouse
islets, Orai1 and Orai3 levels were nearly equivalent, and
these were the most abundantly expressed Orai isoforms.
Orai3 was the mostly highly expressed isoform in INS-1
cells. Analysis of islets from STZ-treated mice revealed
a specific reduction in STIM1 gene and protein expression
(Fig. 2F–H), whereas no differences in STIM2, Orai1,
Orai2, or Orai3 gene expression were observed between
saline and STZ-treated groups (Fig. 2F).
Homozygous STIM1 KO mice experience perinatal le-
thality, and STIM2 KO mice die shortly after birth (28,29).
To test whether KO of STIM1 was sufficient to impair
glucose-stimulated Ca2+ responses, islets from STIM1flox/flox
mice were transduced with an adenovirus encoding Cre
recombinase. STIM1 protein was effectively reduced in
Cre-transduced islets from STIMflox/flox mice (pSTIM1KO)
(Fig. 2I). Consistent with the results observed in islets
isolated from STZ-treated mice, the amplitude of the phase
1 and 2 responses were reduced in pSTIM1KO islets (Fig.
2J–M). Similar to the results obtained in islets from STZ-
treated mice, the oscillatory period was also reduced in
pSTIM1KO islets (Fig. 2E and N). However, this was noted
to be in contrast to the increased oscillatory period ob-
served in islets treated with ML-9 or 2-APB (Fig. 1H).
Next, we tested whether the expression of SOCE mo-
lecular constituents was altered in islets from human
cadaveric donors with T2D. This analysis revealed a signif-
icant reduction in STIM1 and Orai2 gene expression and
a trend toward reduced Orai1 mRNA expression in islets
from donors with T2D (P = 0.06) (Fig. 3A). Immunoblot
analysis revealed no change in Orai1 or Orai2 protein
levels (data not shown), but STIM1 protein expression
was reduced by ;40% in islets from donors with T2D
(Fig. 3B and C). Next, Pearson correlation tests were
used to assess the relationships between donor BMI
and STIM1 mRNA levels. In islets from donors without
diabetes, STIM1mRNA levels were positively correlated
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with BMI (R2 = 0.573; P = 0.048), whereas this corre-
lation was lost in donors with T2D (Fig. 3D).
Proinflammatory Cytokine Stress Reduced b-Cell
STIM1 mRNA and Protein Expression and Led to
Impaired SOCE
To define whether STIM1 expression was similarly im-
pacted under in vitro diabetic stress conditions, human
and mouse islets were treated with a mixture of proin-
flammatory cytokines, consisting of 5 ng/mL IL-1b,
100 ng/mL IFN-g, and 10 ng/mL TNF-a for 24 h Cytokine
treatment led to a significant reduction in STIM1 protein
levels in human and mouse islets (Fig. 4A and B). Because
INS-1 cells are known to be more sensitive to proinflam-
matory cytokines (30), INS-1 cells were treated with in-
creasing doses of IL-1b alone for 24 h. Consistent with the
results obtained in human and mouse islets, STIM1 pro-
tein and mRNA levels decreased significantly with IL-1b
treatment (Fig. 4C–E), whereas no reductions in STIM2,
Orai1, Orai2, or Orai3 mRNA expression were observed
(Fig. 4C). Reduced STIM1 expression correlated with
a dose-dependent reduction in SOCE (Fig. 4F and G).
Quantitation of the DF in response to TG was reduced in
parallel, suggesting impaired ER Ca2+ storage in IL-1b–
treated INS-1 cells (Fig. 4H).
To test these findings in another model of diabetic
stress, INS-1 cells were treated with 0.5 mmol/L palmitate
combined with 25 mmol/L glucose to mimic glucolipotox-
icity (GLT). In GLT-treated INS-1 cells, both STIM1 and
STIM2 mRNA levels were reduced (Fig. 4I), and STIM1
protein was reduced in parallel (Fig. 4J). No significant
change in Orai1–3 mRNA levels was observed. SOCE was
significantly decreased by GLT treatment as well as pal-
mitate treatment alone (Fig. 4K and L). Similar to the
results observed with IL-1b treatment, the DF response to
TG was reduced in both palmitate and GLT-treated INS-1
cells (Fig. 4K and Supplementary Fig. 2A and B).
Figure 2—Loss of STIM1 expression led to impaired islet glucose–stimulated Ca2+ oscillations. Islets were isolated from saline and STZ-
treated C57BL/6J mice and loaded with Fura-2 AM for Ca2+ imaging experiments in the presence of 5.5 mmol/L glucose. A and B:
Representative cytosolic Ca2+ recording of islets after stimulation with 15 mmol/L glucose. Quantification of the average phase 1 amplitude
(C ), phase 2 (oscillation) amplitude (D), and phase 2 period (E). F–H: Islets were isolated from saline and STZ-treated C57BL/6J mice. F: Total
islet RNA was subjected to qRT-PCR for the quantification of STIM and Orai isoform mRNA expression levels (normalized to actin mRNA
expression). G and H: Immunoblot was performed using antibodies against STIM1 and actin. Shown is a representative immunoblot and the
mean 6 SEM of STIM1 protein levels from multiple replicates. *P , 0.05 compared with islets from saline-treated mice. I–N: Islets isolated
fromSTIM1flox/floxmice were transducedwith a Cre-expressing adenovirus (pSTIM1KO) or empty viral control (WT). I: ReducedSTIM1 protein
expression in pSTIM1KO islets was confirmed by immunoblot. J–N: pSTIM1KO islets were loaded with Fura-2 AM, and Ca2+ imaging was
performed. J and K: Representative cytosolic Ca2+ recording after stimulation with 15 mmol/L glucose. Quantification of the average phase
1 amplitude (L), phase 2 (oscillation) amplitude (M), and oscillation period (N); n = 4–5 per group. *P, 0.05 comparedwithWT islets. Numbers
of replicates for each experiment are indicated by the open circles. Cont, control.
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Taken together, our data identified a specific and con-
sistent reduction in STIM1 expression in islets and
pancreatic b-cells across a variety of diabetes models. More-
over, pharmacologic inhibition of SOCE reduced GSIS and
impaired glucose-stimulated Ca2+ oscillations, whereas the
effects on calcium oscillations were partially phenocopied
by STIM1 knockdown in islets.
STIM1 Deletion Reduced b-Cell SOCE, ER Ca2+
Storage, and GSIS
Off-target effects of chemical SOCE inhibitors have been
reported (31), including an effect of 2-APB on inositol
triphosphate receptor activity. To this end, CRISPR/Cas9
genome editing was used to create an INS-1 STIM1 KO
cell line (KO cells). Gene expression analysis of KO cells
demonstrated the absence of STIM1 mRNA, with no com-
pensatory upregulation of other SOCE constituents in-
cluding STIM2 and Orai1–3 (Fig. 5A). In addition, no
change in Serca2b expression was observed. Similar to
the findings observed in our in vitro models of cytokine,
GLT, and palmitate-stress, the DF response to TG was
reduced in STIM1 KO cells (Supplementary Fig. 2C and D).
In addition, SOCE measured in response to TG and car-
bachol treatment was significantly reduced in KO cells (Fig.
5B–D), whereas no further reduction in SOCE was ob-
served when STIM1 KO cells were treated with IL-1b
(Supplementary Fig. 3A and B), GLT (Supplementary
Fig. 3C and D), ML-9, or 2-APB (Supplementary Fig. 3E).
To more definitively examine the effect of STIM1 KO
on ER Ca2+ levels, WT and KO cells were transduced with
the ER-targeted, FRET-based, D4ER Cameleon probe, and
imaging experiments were performed in Ca2+ containing
HBSS buffer. Under basal conditions, STIM1KO cells dis-
played a lower FRET/donor ratio, which is indicative of
decreased ER Ca2+ levels (Fig. 5E). To confirm these
findings, FLIM analysis was performed to measure the
lifetime of the D4ER cyan fluorescent protein (CFP) donor.
As expected, the lifetime of the D4ER donor was increased
in KO cells compared with WT cells (Fig. 5F and Supple-
mentary Fig. 3F). Finally, GSIS was measured in WT and
STIM1 KO cells. Similar to results obtained with pharma-
cologic SOCE inhibition (Fig. 1D), STIM1 deletion signif-
icantly reduced GSIS, whereas no effect on basal insulin
secretion was observed (Fig. 5G).
Loss of STIM1 Increased b-Cell ER Stress
We hypothesized reductions in ER Ca2+ levels arising from
impaired SOCE may likewise impact stress responses in
STIM1 KO cells. To test this, WT and KO cells were treated
with 25 mmol/L glucose + 0.5 mmol/L palmitate (GLT) or
10 mmol/L TM for 3 h. In response to both GLT and TM, an
increase in the spliced/unspliced XBP-1 ratio was observed
in KO cells (Fig. 6A). Moreover, STIM1 KO cells exhibited
increased cleaved caspase-3 activation in response to IL-1b
treatment (Fig. 6B and C). Next, to compare acute and
chronic STIM1 loss, siRNA-mediated STIM1 knockdown
was performed in WT INS-1 cells, resulting in an ;50%
reduction in STIM1 gene and protein expression (Fig. 6D
and E). Similar to the results observed in STIM1KO cells,
siRNA-treated cells exhibited significantly higher levels
of spliced/unspliced XBP-1 in response to TM treatment
(Fig. 6F). Finally, to determine whether these functional
changes correlated with changes in ER ultrastructure,
electron micrographic images of WT and KO cells were
analyzed. In contrast to regularly spaced stacks of ER
observed in WT cells, the ER was swollen and dilated in
STIM1 KO cells (Fig. 6G). Taken together, these data
indicate that STIM1 loss is associated with changes in
ER morphology and increased b-cell susceptibility to TM-,
cytokine-, and GLT-mediated stress.
STIM1 Overexpression Restored ER Ca2+ Levels and
Improved Insulin Secretion in Human Islets From
Donors With T2D
To test the effects of STIM1 gain of function, WT and KO
cells were transduced with a STIM1-expressing adenovirus,
and a dose-dependent increase in STIM1 expression was
observed (Fig. 7A). Consistent with this, a dose-dependent
increase in SOCE was also observed with STIM1 over-
expression (Fig. 7B and C). Next, to test the effect of
STIM1 overexpression on ER Ca2+ levels, STIM1 KO cells
were transduced with the D4ER-expressing adenovirus in
combination with either an empty vector or STIM1-
expressing adenovirus. Under steady-state conditions,
STIM1 restoration led to an increase in the FRET/CFP
ratio in KO cells (Fig. 7D). This result was confirmed by
FLIM analysis, in which the lifetime of the D4ER donor
probe was significantly reduced by STIM1 overexpression
in KO cells (Fig. 7E).
Next, FRET analysis was performed to dynamically mon-
itor ER Ca2+ storage in WT and STIM1 KO cells transduced
with an empty virus or STIM1-expressing adenovirus. No
Figure 3—STIM1 expression was reduced in human islets from
donors with T2D. Human islets were obtained from seven to nine
donors without diabetes (ND donors) and 7–11 donors with T2D. A:
Total RNA was isolated and subjected to qRT-PCR for quantification
of STIM and Orai isoform expression levels. B and C: Total islet
protein was isolated and immunoblot was performed using anti-
bodies against STIM1 and actin. *P , 0.05 compared with ND
donors. D: Correlation analysis between islet STIM1 mRNA levels
and donor BMI.
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differences in the FRET/CFP ratio were observed at baseline
under Ca2+-free conditions. The initial response to carbachol
was similar between the groups. In contrast, STIM1 KO cells
demonstrated impaired ER Ca2+ restoration after ER Ca2+
depletion when Ca2+ was added to the buffer. Moreover, ER
Ca2+ restoration was significantly improved in KO cells by
STIM1 overexpression (Fig. 7F–H).
Next, we tested whether STIM1 overexpression was
sufficient to protect against IL-1b–mediated activation of
cleaved caspase 3. In both WT and STIM1 KO cells, STIM1
overexpression reduced cleaved caspase 3 protein levels
(Fig. 7I and J). Consistent with this, STIM1 overexpression
rescued SOCE under conditions of cytokine stress (Supple-
mentary Fig. 4A and B). Finally, human cadaveric islets from
donors with T2Dwere transduced with the STIM1-expressing
adenovirus or an empty viral control (Fig. 7K). Compared
with islets transduced with empty virus, GSIS was signifi-
cantly improved in STIM1-transduced human islets (Fig. 7L).
DISCUSSION
Recent findings suggest that ER dysfunction triggers
a range of chronic human diseases, including Alzheimer
disease, Parkinson disease, atherosclerosis, and diabetes
Figure 4—STIM1 expression was decreased under proinflammatory cytokine stress and GLT. Islets from human donors without diabetes (A)
and C57BL/6J mice (B) were treated with 5 ng/mL IL-1b, 100 ng/mL IFN-g, and 10 ng/mL TNF-a for 24 h. Immunoblot was performed using
antibodies against STIM1 and actin. C: INS-1 b-cells were treated with 5 ng/mL IL-1b for 24 h; total RNA was isolated and subjected to qRT-
PCR for quantification of STIM and Orai isoform mRNA expression levels (normalized to actin mRNA expression). D–H: INS-1 b-cells were
treated with 0, 0.05, 0.5, or 5 ng/mL IL-1b, for 24 h. Total RNA and protein were isolated and subjected to qRT-PCR for quantification of
STIM mRNA (D) and protein levels (E). F and G: Cytosolic Ca2+ imaging was performed to quantitate SOCE in IL-1b–treated INS-1
cells in the presence of 5.5 mmol/L glucose, 200 mmol/L diazoxide, and 10 mmol/L verapamil (Dz + V). H: ER Ca2+ levels were indirectly esti-
mated by quantitating the DF/F0 response to TG. I–L: INS-1 b-cells were treated with a combination of 0.5 mmol/L palmitate + 25 mmol/L
glucose (GLT), 0.5 mmol/L palmitate + 11 mmol/L glucose (Palmitate), or vehicle control + 11 mmol/L glucose (Cont) for 24 h (I). Total
RNA was isolated from control and GLT-treated INS-1 cells and subjected to qRT-PCR for quantification of STIM and Orai mRNA expression
levels. J: Immunoblot for STIM1 and actin was performed in INS-1 cells treated with GLT for 24 h. K and L: Cytosolic Ca2+ imaging was per-
formed to quantitate SOCE in GLT and palmitate-treated INS-1 cells. The number of replicates for each experiment are indicated by the
open circles. *P , 0.05 compared with control conditions or for indicated comparisons.
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(32–35). In the pancreatic b-cell, a key determinant of ER
function is the maintenance of robust levels of intralumi-
nal Ca2+, which is required for protein folding and a num-
ber of key cellular signaling events. Reductions in b-cell ER
Ca2+ occur in response to proinflammatory and glucolipo-
toxic stress and contribute to the pathophysiology of both
major forms of diabetes. Under normal conditions, ER Ca2+
store depletion triggers a tightly regulated rescue mecha-
nism known as SOCE or Ca2+ release-activated Ca2+
current. This process was first proposed by Putney (36).
However, a complete understanding of the SOCE molec-
ular complex remained elusive until 2005, when STIM1
was identified as the long sought after “ER Ca2+ sensor” (8).
Since that time, SOCE has been accepted as a predominant
pathway of Ca2+ entry into nonexcitable cells, where it has
been shown to regulate a variety of cellular functions,
including proliferation, growth, inflammation, apoptosis,
and lipogenesis (14,37). To date, however, a role for SOCE
in excitable and secretory cells, including the pancreatic
b-cell, has remained incompletely explored.
Here, we show impairment of glucose-stimulated Ca2+
oscillations and reduced insulin secretion in response to
pharmacologic SOCE inhibition and under conditions of
STIM1 loss. Across multiple models of diabetes, our results
revealed a preferential reduction in STIM1 mRNA and
protein levels in pancreatic islets and b-cells. Furthermore,
we show that the genetic loss of STIM1 was sufficient to
reduce b-cell SOCE, glucose-stimulated Ca2+ oscillations,
and insulin secretion, while simultaneously increasing
susceptibility to ER stress and cell death in response to
glucolipotoxic and proinflammatory conditions. Previ-
ously, STIM1, Orai1, and TRPC1 have been identified as
key constituents of the b-cell SOCE complex, whereas
pharmacologic SOCE inhibition or a dominant-negative
form of Orai1 or TRPC1 was shown to reduce insulin
secretion in rat islets and clonal b-cell lines (11). Our data
highlight an expanded role for STIM1 in nucleating this
process and implicate a loss of STIM1 and impaired SOCE
in b-cell dysfunction under diabetic conditions.
The impact of altered SOCE on insulin exocytosis is
likely to be multifactorial. However, a key finding from our
study is that SOCE inhibition and STIM1 loss impaired
first-phase glucose-stimulated cytosolic Ca2+ responses as
well as glucose-induced Ca2+ oscillations. These effects
were similar to those observed in a mouse model of
SERCA2 haploinsufficiency, where reductions in SERCA2
were shown to reduce b-cell ER Ca2+ levels and cytosolic
Ca2+ oscillations (4). Thus, our data offer additional sup-
port to the notion that ER Ca2+ stores shape the archi-
tecture of glucose-induced Ca2+ oscillations as well as the
b-cell insulin secretory response. Intriguingly, STIM1 was
shown recently to interact with the sulfonylurea receptor
1 subunit of the KATP channel and regulate b-cell KATP
activity in MIN6 cells (19). In this report, short hairpin
RNA–mediated STIM1 knockdown reduced KATP channel
activation, whereas STIM1 reconstitution restored KATP
activity, suggesting that reductions in insulin secretion
with STIM1 loss/SOCE inhibition may also result from
Figure 5—STIM1 deletion led to impaired SOCE, reduced ER Ca2+ levels, and decreased GSIS. CRISPR/Cas-9 genomic editing was used to
create an INS-1 832/13 STIM1KO cell line. A: Total RNA was isolated and subjected to qRT-PCR for quantification of STIM and Orai
isoforms and SERCA2b mRNA levels. Numbers of replicates are indicated by the open circles and black squares. Cytosolic Ca2+ imaging
was performed to quantitate SOCE in STIM1KO and WT cells in response to 3 mmol/L TG (B) and 200 mmol/L carbachol (CCh) (C ), which
were used to empty ER Ca2+ stores in the presence of 5.5 mmol/L glucose, 200 mmol/L diazoxide, and 10 mmol/L verapamil (Dz + V). D:
Quantitative assessment of SOCE in WT and KO cells; the numbers of replicates are indicated by the open circles. E and F: ER Ca2+ levels
were compared in WT and STIM1KO cells transduced with a D4ER adenovirus, using a confocal microscope imaging system. E:
FRET/CFP ratios were acquired in HBSS buffer containing 2 mmol/L Ca2+ in WT cells (n = 65) and KO cells (n = 53). F: Average donor
lifetime from FLIM analysis of at least 20 cells from each group. For A, D, E, and F, *P , 0.05 compared with control WT cells. G: GSIS in
WT and KO cells was measured and normalized to total protein levels. The number of replicates are indicated by the open circles. *P ,
0.05 compared with 2.5 mmol/L glucose; #P , 0.05 compared with WT cells treated with 16.7 mmol/L glucose.
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impaired KATP activity (19). A hallmark of advanced human
T2D is the development of an impaired response to
sulfonylurea medications, which act to close the KATP
channel to increase insulin secretion (38–40). In our
data, we observed a positive correlation between donor
BMI and STIM1 expression levels in islets from humans
without diabetes, but this correlation was lost in donors
with T2D. Moreover, our data revealed that STIM1 recon-
stitution in islets from donors with T2D improved GSIS.
These findings imply that STIM1 upregulation may be
a compensatory response observed in islets from obese
donors that is responsible for the initial maintenance of in-
sulin secretion in the face of advancing insulin resistance. By
corollary, our data suggest that reductions in STIM1 could
play an important role in the development of impaired
insulin secretion and loss of secretagogue efficacy in T2D.
Pathologic reductions in b-cell ER Ca2+ levels have been
linked with the development of ER stress. Thus, reduced
ER Ca2+ levels in STIM1-deficient cells led us to hypoth-
esize an additional role for STIM1 in ER stress signaling.
Indeed, we found that genetic loss of STIM1 as well as
STIM1 knockdown increased b-cell susceptibility to
TM-induced ER stress and proinflammatory cytokine–
induced cell death. In contrast, STIM1 overexpression
was able to protect against proinflammatory cytokine–induced
activation of cleaved caspase 3. Recent reports have implicated
SERCA2 loss (4,12,41), as well as RyR-mediated ER Ca2+
release, in the activation of ER stress signaling in diabetes
(13). Here, we have identified an additional role for SOCE
dysfunction and STIM1 loss in this phenotype. These
observations are in agreement with findings observed in
other cell types, including both excitable cells in the central
nervous system as well as nonexcitable mouse embryonic
fibroblasts (42,43).
Our data revealed a consistent loss of STIM1 in the
b-cell across multiple models of diabetes. However, a po-
tential caveat to our observation of reduced STIM1 ex-
pression in islets from human donors with T2D is that loss
of islet b-cell number may also accompany T2D (44). In
addition, STIM1 did not appear as differentially regulated
in a microarray analysis of laser-captured islets from
human donors with T2D (45). However, we were able to
confirm the b-cell downregulation of STIM1 expression
using in vitro and ex vivo diabetogenic stress in isolated
islets and INS-1 b-cells. Among these models, we found
that STIM1 mRNA and protein levels were reduced by
proinflammatory cytokines, which are known to be a prom-
inent component of the pathophysiology of type 1 diabetes
(46). Additional studies are needed to define whether b-cell
SOCE dysregulation may also be present in human type
1 diabetes.
We have not yet explored the intervening pathways that
lead to loss of b-cell STIM1 expression under diabetic
conditions. In other cell types, the inhibition of both AKT
and mammalian target of rapamycin signaling led to
a similar loss of STIM1 (47). Notably, both of these
Figure 6—STIM1 deficient cells exhibited increased susceptibility to ER stress. A: STIM1KO andWT INS-1 cells were treated with or without
25 mmol/L glucose + 0.5 mmol/L BSA-conjugated palmitate (GLT) or 10 mmol/L TM for 3 h. Total RNA was isolated and subjected to qRT-
PCR. Shown are the average spliced/unspliced XBP-1 ratios. *P , 0.05, compared with control (Cont) conditions; #P , 0.05, for indicated
comparisons.B andC: STIM1KOandWT INS-1 cells were treatedwith or without 5 ng/mL IL-1b for 24 h. Immunoblot analysis was performed
using antibodies against STIM1, cleaved caspase-3, and actin. Quantitative protein levels are shown graphically. *P , 0.05 compared with
control conditions; #P , 0.05 compared with IL-1b–treated WT group. D and E: INS-1 cells were transfected with siRNAs against STIM1
(siSTIM1) or an siControl. Total RNA and protein were isolated and subjected to qRT-PCR and immunoblot to confirm reduced STIM1mRNA
and protein expression. F: siSTIM1- and siControl-transfected cells were treated with 10mmol/L TM for 3 h, and the spliced/unspliced XBP-1
mRNA ratios were quantitated using qRT-PCR. *P, 0.05 compared with control conditions or for indicated comparisons. G: STIM1KO and
WT INS-1 cells were treated with 10 mmol/L TM for 24 h, fixed, and analyzed by electron microscopy. Representative images of the b-cell ER
ultrastructure, indicated by dotted lines in WT and KO cells (scale bars = 2 mm). For each experiment, the numbers of replicates are indicated
by the open circles.
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signaling pathways play an essential role in the mainte-
nance of b-cell health and function (48,49). In addition,
nuclear factor-kB has been shown to directly bind and
modulate STIM1 gene promoter activity in other cell types
(50). We and others have previously identified a deleterious
effect of nuclear factor-kB–mediated nitric oxide signaling
on ER calcium regulation (41,51), and this will be tested in
follow-up studies. Here, we focused on the loss of STIM1
expression as the cause of impaired SOCE. However, in
other cell types, mislocalization or impaired formation of
the SOCE complex has been observed under disease con-
ditions (52). Finally, STIM2 overexpression has been
shown to have a strong negative effect on endogenous
SOCE in human embryonic kidney 293, PC12, A7r5, and
Jurkat T cells (53). Thus, our observation of impaired
SOCE in STIM1 KO cells and a reduced Ca2+ oscillatory
amplitude in STIM1-deleted islets could also be partly
explained by alterations in the STIM1/STIM2 ratio.
Notwithstanding these uncertainties, our findings in-
dicate that the loss of STIM1 expression and impaired
SOCE in rodent and human models of diabetes resulted in
decreased b-cell ER Ca2+ levels, increased ER stress, ab-
normal Ca2+ oscillation patterns, and decreased insulin
secretion (Fig. 8). The identification of this novel role for
Figure 7—STIM1 overexpression restored ER Ca2+ levels and improved insulin secretion in human islets from donors with T2D. A: STIM1KO
and WT INS-1 cells were transduced with an adenovirus encoding human STIM1 in increasing concentrations (shown as plaque-forming
units [pfu]/mL). Immunoblot was performed using antibodies against STIM1 and actin. B and C: SOCE was measured in STIM1KO cells and
WT INS-1 cells that had been transduced with STIM1-expressing adenovirus (Ad-STIM1) or an empty adenoviral control (EV) in the presence
of 5.5 mmol/L glucose, 200 mmol/L diazoxide, and 10 mmol/L verapamil (Dz + V). Quantitative results are shown as the DF/F0; *P , 0.05
compared withWT+EV; #P, 0.05 compared with EV-treated STIM1KO cells.D–H: ER Ca2+ analysis using FRET and FLIM was performed in
D4ER-expressing STIM1KO cells and WT INS-1 cells that had been transduced with Ad-STIM1 or EV. D: Quantitation of FRET/CFP ratio of
the D4ER probe at baseline in 2 mmol/L Ca2+ containing HBSS buffer. E: FLIM analysis for the D4ER donor probe is shown graphically as the
relative average donor lifetime. For D and E, *P , 0.05 compared with WT cells. #P , 0.05 compared with STIM1 KO cells + EV. F: FRET
analysis was performed in WT and STIM1 KO cells transduced with Ad-STIM1 or EV in the presence of 5.5 mmol/L glucose. Cch, carbachol.
G and H: Carbachol-induced reductions in ER Ca2+ levels and ER Ca2+ refilling after the addition of 2 mmol/L Ca2+; results are shown
quantitatively as the change in the FRET ratio (DR); *P , 0.05 compared with WT cells; #P , 0.05 compared with STIM1 KO cells + EV. I:
STIM1KO cells and WT INS-1 cells were transduced with STIM1-expressing adenovirus or EV control and treated with or without 5 ng/mL
IL-1b for 24 h. Immunoblot analysis was performed using antibodies against STIM1, cleaved caspase-3, and actin. J: Relative expression
levels of cleaved caspase 3 are shown graphically; *P , 0.05, compared with control conditions; #P , 0.05 compared for indicated
comparisons.K and L: Human islets from two donorswith T2Dwere transducedwith STIM1-expressing adenovirus (33 106 pfu/mL) or EV.K:
Immunoblot was performed to verify STIM1 overexpression. L: GSIS from two separate experiments of two donors with four replicates each
was measured and normalized to total protein content; *P , 0.05 compared with high-glucose conditions in EV-treated islets. For each
experiment, the numbers of replicates are indicated by the open circles.
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STIM1 in the pathogenesis of diabetes suggests that the
restoration of STIM1 expression and/or reconstitution of
SOCE has the potential to improve b-cell health and
function.
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